Overall, these findings reveal a tumor-suppressive role of METTL1-mediated tRNA m7G modification in breast cancer, selectively promoting translation of GADD45A and RB1 to induce G2/M cell cycle arrest, suggesting a potential strategy to improve CDK4/6 inhibitor therapy (20). The gene discussed is CDK4; the disease is neoplasm.